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Vitamin D receptor (VDR) agonists are currently the agents of choice for the treatment of psoriasis, a skin inﬂammatory
indication that is believed to involve an autoimmune component. 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], the biologically
active metabolite of vitamin D, has shown eﬃcacy in animal autoimmune disease models of multiple sclerosis, rheumatoid
arthritis, inﬂammatory bowel disease, and type I diabetes. However, the side eﬀect of 1,25-(OH)2D3 and its synthetic secosteroidal
analogs is hypercalcemia, which is a major impediment in their clinical development for autoimmune diseases. Hypercalcemia
develops as a result of the action of VDR agonists on the intestine. Here, we describe the identiﬁcation of a VDR modulator
(VDRM) compound A that was transcriptionally less active in intestinal cells and as a result exhibited less calcemic activity in
vivo than 1,25-(OH)2D3. Cytokine analysis indicated that the VDRM not only modulated the T-helper cell balance from Th1 to
Th2 eﬀector function but also inhibited Th17 diﬀerentiation. Finally, we demonstrate that the oral administration of compound
A inhibited the induction and progress of experimental autoimmune encephalomyelitis in mice without causing hypercalcemia.
1.Introduction
Experimental autoimmune encephalomyelitis (EAE), an
inﬂammatory demyelinating disease induced in mice by
immunization with myelin components, displays patholog-
ical and clinical resemblances to the human demyelinating
disease multiple sclerosis (MS). EAE and MS are character-
izedclinicallybyneurodegenerationandparalysisandpatho-
logically by demyelination and inﬁltration of lymphocytes
and monocytes into the CNS [1]. Epidemiological studies
have shown a global north-south gradient of MS incidence
and mortality rates. In other words, geographic distribution
of MS prevalence increases with increasing latitude on
both sides of the equator [2, 3]. A strong correlation
between latitude and MS incidence could be explained by
the decreased exposure of susceptible population to UV
radiation. Since UV light is required for vitamin D synthesis
intheskin,anumberofstudieshaveexploredtheconnection
between vitamin D and MS. In a prospective epidemiological
study (Nurses’ Health Study) involving 187,000 women from
1980 to 2001, intake of vitamin D from supplements was
inversely associated with the risk of MS [4]. The notion that
vitamin D could be involved in the regulation of disease
activity of MS is further strengthened from the observa-
tion that lower serum 25-hydroxyvitamin D levels were
observed during MS relapses than those during remission
[5]. Importantly, pharmacological doses of the biologically
active form of vitamin D (1,25-dihydroxyvitamin D3; 1,25-
(OH)2D3)greatlyreducedtheincidenceofdiseaseintheEAE
model [6].
1,25-(OH)2D3 is being increasingly recognized as an
important immunomodulatory agent apart from its classical2 Autoimmune Diseases
role in mineral homeostasis and maintenance of skeletal
architecture. 1,25-(OH)2D3 and its synthetic analogs exert
these eﬀects by binding to the vitamin D receptor (VDR)
thatbelongstothesteroid/thyroidhormonenuclearreceptor
superfamily [7, 8]. VDR, a ligand-dependent transcription
factor, functions as a heterodimer with another nuclear
receptor, namely, retinoid X receptor (RXR). Upon ligand
binding, VDR undergoes a conformational change that
promotes RXR-VDR heterodimerization [9, 10]. Liganded
RXR-VDR heterodimer translocates to the nucleus, binds
to the vitamin D responsive elements (VDREs) present
in the promoter regions of responsive genes, and recruits
chromatin modifying enzymatic activities through interac-
tion with coactivators and DRIP complex, which ultimately
leads to the initiation of transcription [11]. 1,25-(OH)2D3
and its synthetic analogs act as immunomodulators with
immunoregulatory and anti-inﬂammatory properties [3, 12,
13] and as a result have shown eﬃcacy in various in vitro and
in vivo models of autoimmune diseases (arthritis, multiple
sclerosis, inﬂammatory bowel disease, and EAE). However,
the major hurdle facing the translation of basic and applied
research to therapeutic ligands is hypercalcemia associated
with the current generation of VDR ligands. Therefore, there
is a clinical unmet need for the identiﬁcation of novel VDR
ligands that exhibit an improved therapeutic index.
1,25-(OH)2D3 is a secosteroidal compound and most of
the VDR ligands that have been described to date have a
secosteroidal backbone [14]. Administration of VDR ligands
results in hypercalcemia by increasing calcium absorption
from the intestine. Consistent with this view, VDR-null mice
display marked hypocalcemia [15]. 1,25-(OH)2D3 action
on duodenal enterocytes induces calcium transport protein
1/transient receptor potential vanilloid epithelial calcium
channel 6 (CaT1/TRPV6) expression, which channels cal-
cium from the intestinal lumen into the cell [16]. VDR
ligands also induce the expression of an EF-hand-containing
carrier protein, calbindin-9k that ferries the bound calcium
from the apical to the basolateral membrane [16]. Therefore,
a tissue selective/cell-context-dependent VDR ligand that is
transcriptionally less active in intestinal cells but a potent
agonist in immune cells may exhibit reduced hypercalcemia
liability and a better therapeutic index required for the
treatmentofMS.Sincenonsteroidalstructureshaveprovided
tissue selective estrogen receptor modulators (SERMs) that
are agonists in bone and antagonists or transcriptionally
inactive in breast and uterine cells [17, 18], we have
identiﬁed and characterized a nonsecosteroidal analog of
vitamin D, compound A, as a nonsecosteroidal VDRM. We
demonstrate that compound A functions as a potent and
eﬃcacious agonist in human peripheral blood mononu-
clear cells (PBMCs) and osteoblasts but exhibits attenu-
ated transcriptional activity in intestinal cells. In addition,
compound A modulates the balance of Th1 versus Th2
cytokine proﬁle. A plausible mechanism of this shift could
be due to the induction of GATA3, a master regulator of
Th2 diﬀerentiation. The cell-context-dependent activity of
compoundAalsotranslatedinvivoinreducedhypercalcemic
liability in a murine model of hypercalcemia. We also
demonstrate that in a preclinical murine EAE model of
MS, compound A delayed the onset of EAE and reduced
the severity of the disease at a noncalcemic dose. Finally,
splenocytes obtained from VDRM-treated MOG-induced
EAE animals showed attenuated T cell proliferation response
to the MOG peptide antigen and showed increased IL-10
and reduced interferon-γ (IFN-γ) production. Furthermore,
VDRM signiﬁcantly inhibited Th17 diﬀerentiation. Thus,
compound A represents a novel class of VDRMs that could
be eﬃcacious for treating autoimmune diseases such as MS
without hypercalcemia side eﬀect.
2. Methods
2.1. Cell Culture and Transfections. For the RXR-VDR het-
erodimerization assay, Saos-2, cells maintained in DMEM
supplemented with 10% FBS were plated at 5000 cells/well
in a 96-well plate. The next day, cells were transfected
using0.5μLoffugene(RocheDiagnostics,Indianapolis,IN),
100ng of luciferase reporter vector pFR-Luc (Stratagene, La
Jolla, CA) and 10ng each of pVP16-VDR-LBD and pGal4-
RXRα-LBD expression vectors/well. For HeLa and Caco-
2 one-hybrid mammalian transactivation assay, HeLa and
Caco-2 cells, maintained in DMEM supplemented with 10%
FBS, were plated at 5000cells/well in a 96-well plate. Cells
were transfected using 0.5μLo ff u g e n e( R o c h eD i a g n o s t i c s ,
Indianapolis, IN), 100ng of luciferase reporter vector pFR-
Luc (Stratagene, La Jolla, CA), and 10ng of pGal4-VDR-
LBD expression vectors/well. Total DNA amount was kept
constant by adding empty vector DNA as needed. Cells
were treated with the ligand 24 hours after-transfection, and
luciferase activity was quantitated the next day using Steady-
Glo luciferase detection reagent (Promega, Madison, WI).
2.2. Rat Osteocalcin Luciferase (OCN-Luc) Assay. The acti-
vation of osteocalcin VDRE by VDR ligands was evalu-
ated in a rat osteoblast-like cell line (ROS 17/2.8) stably
expressing rat osteocalcin promoter (1.154kb) fused with
luciferase reporter gene. The development of the stably
transfected ROS 17/2.8 cell line (RG-15) containing OCN-
Luc has been described [19]. Conﬂuent RG-15 cells main-
tained in DMEM/F-12 medium (3:1) containing 5% FBS,
300μg/mL G418 at 37◦C were trypsinized (0.25% trypsin)
and plated into white opaque 96-well cell culture plates
(25000 cells/well). After 24 hours, cells (in DMEM/F-
12 medium containing 2% FBS) were treated with the
indicated concentrations of the compounds. After 48 hours
of treatment, the medium was removed, cells were lysed
with 50μLo fl y s i sb u ﬀer (from luciferase reporter assay
system, Roche Diagnostics, Indianapolis, IN) and assayed
for luciferase activity using the Luciferase Reporter Gene
Assay kit from Roche Diagnostics. Aliquots (20μL) of cell
lysates were pipetted into wells of white opaque microtiter
plates (Dynex Technologies, Chantilly, VA) and placed in an
automated injection MLX microtiter plate luminometer. The
luciferase reaction mix (100μL) was injected sequentially
into the wells. The light signals generated in the reactions
were integrated over an interval of two seconds and the
resulting luminescence values were used as a measure of
luciferase activity (relative units).Autoimmune Diseases 3
2.3. TRPV6 Quantitative RT-PCR (Q-PCR) Assay. Human
colon carcinoma, Caco-2, cells, maintained in DMEM (high
g l u c o s ew i t h2 5 m MH e p e sb u ﬀer; Invitrogen, Carlsbad,
CA) supplemented with 10% FBS (Invitrogen, Carlsbad,
CA), were plated at 5500 cell per well in a 96-well plate
in a total volume of 100μL/well. The cells were kept in
the 96-well plate for 6 days to diﬀerentiate them into
small intestinal cells that express TRPV6/CaT1. On day 3
after plating, spent media were removed and replaced with
fresh media (150μL/well). On day 6, the spent media were
removed again and the cells were maintained in treatment
media (180μL/well) (DMEM (low glucose, without phenol
red; Invitrogen, Carlsbad, CA) containing 10% charcoal-
stripped FBS (Hyclone, Logan, UT)). The cells were treated
with various concentrations of VDR ligands prepared in
treatment media (20μL/well). Twenty hours after-treatment,
total RNA was prepared by the RNeasy 96 method, as
described by the manufacturer (Qiagen, Valencia, CA).
The RNA was reversetranscribed and ampliﬁed for human
TRPV6 and GAPDH mRNAs by quantitative RT-PCR
using the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, Foster City, CA). Optimized primer
pairs and probes for human TRPV6 and GAPDH genes were
obtained commercially (Applied Biosystems, Foster City,
CA). Each 20μL quantitative RT-PCR reaction in a 384-
well Taqman PCR plate consisted of forward and reverse
primers (900nM), Taqman probe (200nM), total RNA (4μL
for each well of the 96-well culture plate), and 10μLo f
Taqman Universal PCR Master Mix (Roche Diagnostics,
Indianapolis, IN). Reactions were incubated at 48◦Cf o r3 0
minutes, followed by 10 minutes at 95◦C, and subjected to
40 cycles of PCR (95◦C for 15 seconds followed by 60◦Cf o r
1m i n u t e ) .
2.4. Cytokine Assays in PBMCs. Peripheral blood mononu-
clear cells (PBMCs) were isolated from normal human
donors by sedimentation on Ficoll-Hypaque. Cells were
resuspended in RPMI-1640 supplemented with charcoal-
treated FBS (2%). PBMCs (25 × 106/T75 ﬂask) were treated
with PHA (10μg/mL) and TPA (100ng/mL). The cells
were cultured in the presence of various concentration of
1,25-(OH)2D3 or compound A prepared in RPMI-1640
containing 2% charcoal-treated FBS. Cytokine levels were
quantitated by multiplex ELISA using antibodies speciﬁc
for IL-4, IL-5, IL-13, and IFN-γ. Twenty four hours after-
treatment,totalRNAwasprepared bytheRNeasy96 method
and the RNA was reversetranscribed and ampliﬁed for
human IL-2, IFN-γ, IL-4, IL-10, GATA-3, and GAPDH
mRNAs by quantitative RT-PCR as described in the TRPV6
Q-PCR assay section.
2.5. In Vivo Hypercalcemia Assay. Female, 6-7 weeks old,
DBF1 mice, weighing ∼25g, were purchased from Harlan
Industries (Indianapolis, IN). Mice were housed with ad
libitum access to food (TD 5001 with 0.95% calcium
and 0.67% phosphorus, vitamin D3 4500IU/kg; Teklad,
Madison, WI) and water. Compounds were given daily orally
via gavage for 6 days. Dosing volume was 100μL/mouse with
4 mice in each group. Serum ionized calcium was examined
at 6 hours after last dosing using a Ciba-Corning 634
Ca++/pH Analyzer (Chiron Diagnostics Corp., East Walpole,
MA).
2.6. EAE Model. All mice (C57B6) were age- and sex-
matched (6- to 10-week-old females) at the start of exper-
iments. Mice were immunized subcutaneously at two sites
on the back with 300μgM O G 35−55 peptide (MEVGWYR-
SPFSRVVHLYRNGK,PeptidesInternational,Louisville,KY)
emulsiﬁed in a total of 200μL Complete Freund’s Adjuvant
(CFA; Difco, Detroit, MI) containing 500μg M. tuber-
culosis H37 Ra (Difco) on days 0 and 7, supplemented
with intraperitoneal injections of 500ng pertussis toxin
(Calbiochem, San Diego, CA) on days 0 and 2. Clinical
symptoms of EAE were scored daily by a blinded observer
using the following scale: 0: no symptoms, 0.5: distal weak
or spastic tail, 1: completely limp tail, 1.5: limp tail and hind
limb weakness (feet slip through cage grill), 2.0: unilateral
partial hind limb paralysis, 2.5: bilateral partial hind limb
paralysis, 3.0: complete bilateral hind limb paralysis, 3.5:
complete hind limb and unilateral partial forelimb paralysis,
and 4.0: moribund or death. The data was recorded as
the mean daily clinical score. MOG-immunized mice were
administered orally with vehicle (sesame seed oil), 1,25-
(OH)2D3 (0.5μg/kg/d) or compound A (10μg/kg/d) for 21
days in a total volume of 200μL.
2.7. Splenocyte Cell Culture and Proliferation Assay. Spleno-
cyte cell suspensions were isolated from MOG35−55-
immunized mice atday 28 byhomogenizing spleens between
frosted glass slides (Fisher, Pittsburgh, PA) and removing
RBC with ACK lysing buﬀer (BioWhittaker, Walkersville,
MD). Pooled splenocytes of 6 individual mice from the
same group were plated in triplicate in 96-well round
bottom plate at 2 × 105 cells/well in 200μLc o m p l e t eR P M I
1640 medium (Invitrogen) supplemented with 2 mM L-
glutamine, 25mM HEPES, 100U/mL penicillin, 100μg/mL
streptomycin, 5.5 × 10
−5 M 2-ME, and 5% FCS (all supple-
ments from Invitrogen) containing either 0 and 80μg/mL
of MOG35−55 (Peptides International) or control OVA323−339
peptide (ISQAVHAAHAEINEAGR, Research Genetics, Inc.,
Huntsville, AL) and cultured at 37◦C, 5% CO2.P r o l i f e r a t i o n
was measured by incorporation of [3H]-methylthymidine
(1μCi/well, ICN Radiochemicals, Irvine, CA) during the
last 8 hr of culture using a ﬁltermate harvester (Packard
Instrument Co., Downers Grove, IL) and a 1450 microbeta
liquid scintillation counter (Pharmacia Biotech AB). Results
were determined as mean ± SE from triplicate cultures.
Cytokine levels produced by cultured splenocytes or puriﬁed
CD11c+ dendritic cells from splenocytes (Miltenyi Biotech.)
from MOG35−55-immunized mice were analyzed by remov-
ing 100μL of cell culture supernatant per well after 60h of
culture as described above. Supernatants were ﬁltered using
Millipore plates (Cat # Mabvnob) and stored at −80◦C.
Cytokines were analyzed with LINCOplex mouse cytokine
kit (St. Charles, Miss).
2.8. Na¨ ıve CD4+ T Cell Th17 Diﬀerentiation In Vitro. Na¨ ıve
mouse CD4+ T cells were puriﬁed with AutoMACS and4 Autoimmune Diseases
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Figure 1: Compound A is a nonsecosteroidal VDR ligand. (a) Compound A is a potent agonist in RXR-VDR heterodimerization assay.
SaOS-2 cells were cotransfected with expression vectors encoding Gal4-RXRα-LBD and VP16-VDR-LBD along with a Gal4-responsive
luciferase reporter. After transfection, cells were treated with vehicle or various concentrations of 1,25-(OH)2D3 or compound A, and the
reporter activity was expressed as light units ±SE (standard error). A schematic of the RXR-VDR heterodimerization-based ligand-sensing
assay and the chemical structures of 1,25-(OH)2D3 and compound A are also presented. (b) Compound A is selective for VDR-dependent
transactivation. HeLa cells were cotransfected with various nuclear receptor-Gal4 DNA-binding domain chimeras and the reporter pFR-Luc.
Cells were treated with 100nM compound A. Cell extracts were subsequently assayed for luciferase activity. Data are expressed for each
receptor as fold induction of luciferase activity relative to vehicle-treated cells and represent the mean of four replicates ± SE.
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Figure 2: Compound A induces VDR-mediated gene expression. (a) Compound A is as potent as 1,25-(OH)2D3 in inducing VDR-LBD-
dependent gene expression. Luciferase activity (±SE) of HeLa cells transfected with Gal4-VDR-LBD in a mammalian one-hybrid setting in
thepresenceofvehicleorvariousconcentrationsof1,25-(OH)2D3 orcompoundAisshown.Resultsareinarbitrarylightunitsobtainedfrom
experiments performed in triplicate. (b) Compound A induces VDRE-dependent expression of the rat osteocalcin promoter in osteoblasts.
ROS17/2.8 cells stably transfected with rat osteocalcin reporter (OCN-Luc) were treated with various concentrations of 1,25-(OH)2D3 or
compound A. Results are shown in percentage of the luciferase activity obtained by treating the cells with 1μM 1,25-(OH)2D3.A l lt h e
transfections were performed in triplicate.Autoimmune Diseases 5
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Figure 3: Compound A is less potent and eﬃcacious in inducing the expression of vitamin D-responsive genes in intestinal cells. (a)
Compound A shows weak potency in inducing the expression of endogenous CaT1 gene in diﬀerentiated Caco-2 cells. Taqman Q-PCR
was performed on total RNA prepared from diﬀerentiated Caco-2 cells treated with various concentrations of 1,25-(OH)2D3 or compound
A for 24 hours. Levels of GAPDH mRNA were measured in all the samples, and the results were normalized and presented (±S E )a sr e l a t i v e
light units (RLU) after normalization with the GAPDH transcript levels. (b) Compound A is a poor inducer of endogenous vitamin D-
responsive genes in diﬀerentiated Caco-2 and rat duodenal cells. Taqman Q-PCR was performed on total RNA prepared from Caco-2 and
rat duodenal IEC-6 cells treated with vehicle or 100nM each of 1,25-(OH)2D3 or compound A for 24 hours. The fold induction of CYP24
and calbindin-9k transcripts relative to GAPDH transcripts is shown as mean ± SE of quadruplicate experiments.
diﬀerentiated in vitro. To induce Th17 diﬀerentiation, T
cells were incubated with plate-bound mAbs of anti-CD3
and anti-CD28 with soluble neutralizing mAbs of anti-
IL-4 (5μg/mL), anti-IFNγ (5μg/mL), recombinant IL-6
(10ng/mL), IL-1β (5ng/mL), and TGF-β (5ng/mL) (R&D
System Inc., MN). Cells were then incubated at 37◦C in the
presence or absence of 1,25-(OH2)D3 and compound A for 4
days. Diﬀerentiated Th17 cells were then washed, and equal
numbers of Th17 cells were restimulated with plate-bound
anti-CD3 mAb for 18 h and cell supernatants were used for
measuring levels of IL-17 and IL-22 by ELISA (R&D System
Inc. MN).
2.9. Statistical Analysis. Statistical signiﬁcance versus con-
trol was deﬁned as P<. 05 in Dunnett’s test. In
vitro concentration-response curves were ﬁt using the sig-
moidal/variable slope ﬁtting option in GraphPad Prism
(GraphPad Software, Inc.).
3. Results
3.1. Compound A is a Nonsecosteroidal VDR Agonist. 1,25-
(OH)2D3 and its synthetic analogs induce heterodimer-
ization of VDR with RXR, resulting in the formation
of RXR-VDR heterodimers that are the transcriptionally
active functional units of vitamin D signaling pathway
[9, 10, 13]. This assay is a surrogate for VDR ligand
binding, since VDR ligands and not RXR ligands drive het-
erodimerization between RXR and VDR [10, 13]. The RXR-
VDR heterodimerization-based ligand sensing assay was
performed by cotransfecting SaOS-2 cells with Gal4-RXRα-
LBD and VP16-VDR-LBD expression vectors, along with a
Gal4-responsive reporter. 1,25-(OH)2D3 and compound A
were equipotent in inducing RXR-VDR heterodimerization
with EC50 (concentration of the ligand required for 50%
of the maximal activity) value of 10nM (Figure 1(a)). The
receptor speciﬁcity of nonsecosteroidal VDR ligands was
conﬁrmed by transfecting SaOS-2 cells with the Gal4-DNA
binding domain chimeras of various nuclear receptor-LBD
constructs, along with a Gal4-responsive luciferase reporter.
Compound A induced the expression of the Gal4-dependent
reporter only through Gal4-VDR-LBD and not through
Gal4-TRα,G a l 4 - T R β,G a l 4 - R A R α,G a l 4 - R A R β,G a l 4 - R A R γ,
Gal4-PPARα, Gal4-PPARδ, Gal4-PPARγ,G a l 4 - R X R α,G a l 4 -
RORα, or Gal4-LRH1 LBDs (Figure 1(b)). The structures of
compound A and its diaryl analogs have been reported in a
US patent (no. 7772425).
To determine whether compound A also induces VDRE-
dependent gene expression, a mammalian one-hybrid assay
was performed in HeLa cells to compare the potencies of the
VDRligandsinmediatingGal4-VDR-LBD-dependenttrans-
activation of a Gal4-luciferase reporter construct. Both 1,25-
(OH)2D3 and compound A were potent in inducing VDR-
LBD-mediated transactivation with EC50 values of 55 and
10nM, respectively (Figure 2(a)). To further conﬁrm that6 Autoimmune Diseases
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Figure 4: 1,25-(OH)2D3 shifts the balance from Th1 to Th2 cells in activated PBMCs. Primary cells isolated from donors were stimulated
with TPA (100ng/mL) and PHA (25μL/mL) and treated with vehicle or various concentrations of 1,25-(OH)2D3 for 24 hours. Cytokines
were measured by LINCOplex human cytokine kit on supernatants obtained from vehicle-treated or VDR ligand-treated samples using
antibodies for human IL-4, IL-5, IL-10, and IFN-γ. The amount of IL-4, IL-5, IL-10, and IFN-γ protein levels is shown as mean ± SE of
triplicate experiments.
compound A was potent in inducing VDRE-dependent gene
expressionofanendogenousgene,Ros17.2ratosteosarcoma
cellspermanentlytransfectedwitharatosteocalcinpromoter
luciferase reporter, OCN-Luc (15) were used. 1,25-(OH)2D3
and compound A induced the expression of the rat OCN-
Luc reporter with EC50 values of 0.09 and 9nM, respectively
(Figure 2(b)).
3.2. Compound A Is a Less Potent Agonist than 1,25-(OH)2D3
in Intestinal Cells. VDR ligands result in hypercalcemia
by increasing calcium absorption from the intestine. 1,25-
(OH)2D3 has been shown to induce the expression of epithe-
lial calcium channel, TRPV6, that absorbs calcium from
the intestinal lumen into the duodenal enterocyte [15, 16].
TRPV6 is a vitamin D-responsive gene in vitro and in vivo,
and its expression is drastically reduced in VDR knockout
mice [15, 16, 20]. Therefore, a cell-context-dependent VDR
ligand that is transcriptionally less active in intestinal cells
but a potent agonist in target cells (immune cell) may exhibit
reduced hypercalcemic liability. We next examined the
expression of endogenous TRPV6 gene in Caco-2 cells after
treatmentwithVDRligands.AlthoughCaco-2cellsarecolon
cancer cells, upon density-dependent growth (6–14 days of
culture), they diﬀerentiate into small intestinal like cells that
express many of the markers of small intestine, including
TRPV6, which is normally expressed in the duodenum [20].
These cells upon diﬀerentiation also acquire the machinery
required for VDR ligand-dependent transepithelial calcium
transport(apicaltobasolateral),similartothatofenterocytes
[20, 21]. 1,25-(OH)2D3 (EC50 = 1 6 n M )w a sap o t e n t
inducer of TRPV6 message in diﬀerentiated Caco-2 cells
(Figure 3(a)). In contrast, compound A (EC50 = >1000nM)
showed attenuated potency in inducing the expression of
the endogenous TRPV6 gene in diﬀerentiated Caco-2 cellsAutoimmune Diseases 7
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Figure 5: Compound A augments Th2 and inhibits Th1 cytokines in activated PBMCs. Primary cells isolated from donors were stimulated
with TPA (100ng/mL) and PHA (25μL/mL) and treated with vehicle or various concentrations of compound A for 24 hours. Cytokines
were measured by LINCOplex human cytokine kit on supernatants obtained from vehicle-treated or VDR ligand-treated samples using
antibodies for human IL-4, IL-5, IL-10, and IFN-γ. The amount of IL-4, IL-5, IL-10, and IFN-γ protein levels is shown as mean ± SE of
triplicate experiments.
(Figure 3(a)). These results indicate the cell-type selectivity
of compound A since it was less potent than 1,25-(OH)2D3
in Caco-2 cells.
We also compared compound A with 1,25-(OH)2D3 for
its eﬀect on the expression of two VDRE-dependent genes,
namely, CYP24 and calbindin-9k in diﬀerentiated Caco-2
and IEC-6 (rat duodenal crypt cell line) cells. Treatment of
Caco-2 and IEC-6 cells with 1,25-(OH)2D3 (100nM) for
24 hours resulted in a robust induction of human and rat
CYP24 and calbindin-9k gene expression (Figure 3(b)). In
contrast, compound A was signiﬁcantly less eﬃcacious than
1,25-(OH)2D3 in inducing the expression of endogenous
CYP24andcalbindin-9kinthesecells(Figure 3(b)).Allthese
observations further support the notion that compound A is
a cell-context-dependent VDRM.
3.3. Compound A Is a Potent Agonist in PBMCs. The lesions
of Multiple Sclerosis have shown an increased expression of
proinﬂammatory Th1 cytokines and decreased expression
of Th2 anti-inﬂammatory cytokines IL-4 and IL-10. The
disease is also ameliorated by IL-4 and IL-10 cytokine
therapy in an EAE murine model of multiple sclerosis
[20, 22]. 1,25-(OH)2D3 aﬀects the Th1-Th2 balance, and it
has been shown to augment Th2 cell development which
is accompanied by increased production of IL-4 and IL-10
cytokines in vitro and in vivo [8, 13, 23, 24]. The eﬀect
of 1,25-(OH)2D3 and compound A on cytokine secretion
from PHA/PMA-activated human PBMCs was examined
by multiplex ELISA. 1,25-(OH)2D3 increased IL-10 protein
levels in PHA/PMA-activated human PBMCs with an EC50
value of 2nM (Figure 4). Compound A also increased IL-10
cytokine levels and showed EC50 value of 14nM (Figure 5).
Both 1,25-(OH)2D3 and compound A induced the protein
levels of Th2 cytokines IL-4, IL-5, and IL-10 in a dose-
dependent manner (Figures 4 and 5). However, the levels
of Th1 cytokine IFNγ were decreased in a dose-responsive8 Autoimmune Diseases
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Figure 6: Nonsecosteroidal VDRM is as eﬃcacious as 1,25-(OH)2D3 in modulating cytokine gene expression in activated human PBMCs.
Primary cells isolated from donors were stimulated with TPA (100ng/mL) and PHA (25μL/mL) and treated with vehicle or 100nM each of
1,25-(OH)2D3 andcompoundAfor24hours.Taqman Q-PCRwas performedon RNAobtained formvehicle-treated or VDRligand-treated
samples using primer pairs and probes for IL-2, IL-4, IL-10, IFN-γ,T N F - α, GATA3, and GAPDH. The amount of IL-2, IL-4, IL-10, IFN-γ,
TNF-α, and GATA3 transcripts relative to GAPDH transcripts is shown as mean ± SE of quadruplicate experiments.
manner after 1,25-(OH)2D3 and compound A treatments
(Figures 4 and 5). The EC50 values for IL-4, IL-5, and IL-
10 induction and IFNγ inhibition were 1nM, 0.3nM, 2nM,
and1nM,respectivelyfor1,25-(OH)2D3. Thecorresponding
EC50 values for compound A were 14nM, 4nM, 7nM, and
14nM, respectively (Figures 4 and 5). These results indicate
that compound A is not only a potent agonist in PBMCs but
also shifts the balance from proinﬂammatory Th1 to anti-
inﬂammatory Th2 phenotype.
Furthermore, 1,25-(OH)2D3 a n dc o m p o u n dAw e r e
equally eﬃcacious in decreasing the mRNA expression of
Th1 cytokines IL-2 and IFN-γ and increasing the mRNA
expression of Th2 cytokines IL-4 and IL-10 in activated
PBMCs (Figure 6). In addition, the VDR ligands showedAutoimmune Diseases 9
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Figure 7: Compound A is less calcemic in vivo. 1,25-(OH)2D3 or
compound A was administered in sesame seed oil at indicated doses
to mice by gavage for 6 consecutive days, and blood ionized calcium
was measured 6 hours after the last dose.
equivalent eﬃcacy for decreasing TNF-α expression in acti-
vated PBMCs (Figure 6). 1,25-(OH)2D3 has also been shown
to induce the expression of GATA-3 [13], a master regulator
of Th2 diﬀerentiation [24]. Interestingly, compound A was
also as eﬃcacious as 1,25-(OH)2D3 in augmenting GATA-
3 expression (Figure 6). Therefore, one of the plausible
mechanismsofVDRligand-mediatedTh1toTh2shiftmight
be their ability to induce the expression of basic helix-loop-
helix transcription factor GATA-3. Therefore, compound
A exhibited similar immunomodulatory eﬀects as 1,25-
(OH)2D3 in eﬀector T cell functions.
3.4. Compound A Is Less Calcemic In Vivo. The hypothesis
that the decreased VDR-mediated transcriptional activity of
compound A on TRPV6 gene expression in diﬀerentiated
Caco-2 cells would translate to less calcemic activity in
vivo was tested after oral administration of VDR ligands
to mice in a 6-day murine model of hypercalcemia. Mice
were treated for 5 days with the VDR ligands, and blood-
ionized calcium was measured 24 hours after the last dosing.
1,25-(OH)2D3 caused hypercalcemia in mice when dosed
at 1μg/kg/d. In contrast, compound A showed statistically
signiﬁcant hypercalcemia only at 1000μg/kg/d but not at
300μg/kg/d dose (Figure 7). Therefore, compound A is at
least300timeslesscalcemicthan1,25-(OH)2D3 invivowhen
administered orally.
3.5. Compound A Inhibits Mouse EAE Induction and Severity
In Vivo. Since 1,25-(OH)2D3 and its secosteroidal analogs
have shown eﬃcacy in a number of murine autoimmune
disease models, including EAE [6, 25–27], we next examined
whetheroraladministrationofcompoundAcouldalsoaﬀect
the pathogenesis of EAE without inducing hypercalcemia.
EAE was induced in C57B6 mice by immunization with
MOG peptide and the animals were dosed orally with 1,25-
(OH)2D3 (0.05μg/kg/d) or compound A (10μg/kg/d) daily
for 21 days starting on the day of immunization. Vehicle
control mice were immunized with MOG to induce the
disease, and they were treated with vehicle (sesame seed
oil). CFA control mice were mock immunized with CFA
without MOG peptide and were not treated with vehicle
or VDR ligands. Both 1,25-(OH)2D3 a n dc o m p o u n dA
delayed the appearance of clinical signs of EAE induced
by the MOG peptide. 1,25-(OH)2D3 initially reduced the
severity of the disease until day 17 of the treatment.
However, after day 19, the severity of EAE in 1,25-(OH)2D3-
treated group was indistinguishable from the control groups
(Figure 8(a)). In contrast, compound A treatment signiﬁ-
cantly resulted in less severe course of disease throughout
the treatment period (Figure 8(a)). Microscopic evaluation
of spinal cord neuropathology revealed that compound A
treatment prevented demyelination that was readily visible
asdemyelinatedplaquescontaininginﬁltratingmononuclear
cells in the spinal cord sections of vehicle-treated sample
(Figure 8(b)). Demyelinated areas were reduced in the spinal
cord sections of compound A-treated animals (Figure 8(b)).
Since the major problem associated with 1,25-(OH)2D3
treatmentishypercalcemia,wealsomeasuredserumcalcium
levels at the end of the study. 1,25-(OH)2D3 (0.05μg/kg/d)
resulted in hypercalcemia whereas serum calcium levels were
within the normal range after compound A (10μg/kg/d)
treatment. The diﬀerence of serum Ca++ level between 1,25-
(OH)2D3-and compound A-treated animals was statistically
diﬀerentwhereastherewasnostatisticallydiﬀerencebetween
compound A and vehicle group (Figure 8(c)).
To determine if compound A can modulate antigen
T cell function in EAE, total splenocytes from diseased
mice were stimulated ex vivo with either MOG peptide
or ovalbumin peptide at the indicated concentrations,
and T cell proliferation was measured by 3H-thymidine
incorporation. Compared with vehicle-treated mice, in
vivo treatment with compound A suppressed the speciﬁc
recall response to the encephalitogenic MOG peptide used
in the EAE model (Figure 9(a)) .T h er e c a l lr e s p o n s eo f
MOG-immunized animals was speciﬁc for the MOG pep-
tide and was not observed for ovalbumin (OVA) pep-
tide (Figure 9(a)). Furthermore, both 1,25-(OH)2D3 and
compound A decreased Th1 cytokine IFN-γ production
in MOG-stimulated splenocytes (Figure 9(b)). Interestingly,
both 1,25-(OH)2D3 and compound A also induced IL-
10 cytokine production in isolated CD11c+ dendritic cells
stimulated with 100ng/mL LPS (Figure 9(b)), indicating
that compound A modulated immune response in vivo in
autoimmune pathogenic conditions. Th17 cells have recently
been demonstrated to be the essential pathogenic cells
involved in EAE model. In order to test whether 1,25-
(OH)2D3 and compound A had the direct eﬀect on Th17
diﬀerentiation or Th17 secretion, we performed Th17 diﬀer-
entiation assay in vitro in the presence of these compounds.
As shown in Figure 10, both 1,25-(OH)2D3 and compound
A signiﬁcantly inhibited both IL-17 and IL-22 expression,
indicating that Th17 diﬀerentiation was eﬃciently inhibited
by these compounds. Interestingly, once Th17 cellswerefully
diﬀerentiated, the restimulation of these diﬀerentiated Th17
cells by anti-CD3 mAb to produce IL-17 and IL-22 was
only slighly aﬀected by these compounds (data not shown),10 Autoimmune Diseases
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Figure 8: Oral administration of VDRM is therapeutically eﬃcacious in MOG-induced EAE. (a) Clinical course of EAE after treatment
with VDR ligands. MOG immunized C57B6 mice were orally administered with vehicle, 1,25-(OH)2D3 (0.5μg/kg/d), or compound A
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A group, and 1,25-(OH)2D3-treated group, respectively; ∗∗P<. 01.
indicating that VDRMs were mainly involved in Th17
diﬀerentiation stage.
4. Discussion
The success of nonsteroidal SERMs in limiting the side
eﬀects of estrogen on breast and uterus while still retaining
therapeutic eﬃcacy in bone [17]p r o m p t e du st op u r s u e
identiﬁcation of nonsecosteroidal VDRMs for the treat-
ment of autoimmune diseases, such as MS. In this study,
we have identiﬁed a cell-context-dependent VDRM that
shows attenuated calcemic liability in vivo relative to 1,25-
(OH)2D3.We also show that the nonsecosteroidal VDRM
modulates the balance between Th1 and Th2 cells as wellAutoimmune Diseases 11
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as Th17 diﬀerentiation, since compound A inhibited Th1,
Th17 cytokine production and augmented the production
of Th2 cytokines. Furthermore, the nonsecosteroidal ligand
described herein also displayed therapeutic activity in the
EAE model at a nonhypercalcemic dose. Our results extend
the observations that VDR ligands are eﬃcacious in the
treatment of murine EAE and demonstrate for the ﬁrst time
that a nonsecosteroidal VDRM is therapeutically eﬀective at
an o n h y p e r c a l c e m i cd o s e .
CD4+ T-helper cells could be broadly divided into
diﬀerent eﬀector cells such as Th1, Th2, and Th17 cells based
upon their cytokines elaborated by these cells upon anti-
genic/mitogenic stimulation. The recent evidence indicates
thatTh17cellsarethekeyTcellsinvolvedinthepathogenesis
of autoimmune diseases, whereas Th2 cells are involved in
the pathology of allergic indications and produce IL-4, IL-5,
IL-10, and IL-13 cytokines [24]. 1,25-(OH)2D3 is regarded
as an immunoregulatory hormone that in addition to its
classical role on mineral homeostasis and maintenance of
skeletal architecture also exhibits beneﬁcial eﬀects on Th17-
mediated autoimmune diseases. 1,25-(OH)2D3 has shown
eﬃcacy in several autoimmune disease models, namely,
systemic lupus erythematosus in lpr/lpr mice [28], type I
diabetes in nonobese diabetic mice [29, 30], collage-induced
arthritis [25], EAE [6], experimental autoimmune uveitis
[31], and inﬂammatory bowel disease [26, 32]. Although
1,25-(OH)2D3 has demonstrated eﬃcacy in preventing the
incidence and progression of disease in the EAE model,
the therapeutic activity was associated with accompanying
hypercalcemia (Figure 8).
The VDRM, compound A, displayed many of the
biological actions of 1,25-(OH)2D3. It induced RXR-VDR
heterodimerization (Figure 1(a)), augmented VDR-LBD-
dependent gene expression in HeLa cells (Figure 2(a)),
upregulated the expression of a VDRE-dependent gene,
osteocalcin in osteoblasts (Figure 2(b)), inhibited IFN-γ,
while augmenting IL-4, IL-5, and IL-10 cytokine elaboration
in human PBMCs (Figure 5), and inhibited the expression
of proinﬂammatory cytokines (IL-2, IFN-γ,a n dT N F α)
and induced the expression of anti-inﬂammatory cytokines
IL-4 and IL-10 (Figure 6). It also induced the expression of
GATA-3 (required for Th2 cell diﬀerentiation) in activated
human PBMCs (Figure 6). More importantly, both 1,25-
(OH)2D3 and compound A signiﬁcantly inhibited Th17
cell diﬀerentiation (Figure 10), which is consistent with the
recent observation made by Chang et al. (34). However,
it was signiﬁcantly less potent than its secosteroidal
counterpart in inducing the expression of vitamin D-
responsive genes (TRPV6, Cyp24, and calbindin-9k) in
diﬀerentiated Caco-2 as well as rat duodenal cells (Figure 3).
These results indicate an attenuation of the VDR signaling
pathway to compound A in intestinal cells. At the same
time, the vitamin D signaling pathway still responds to
1,25-(OH)2D3-complexed VDR for vitamin D-dependent
gene expression in Caco-2 cells (Figure 3).
Studies with the VDR knockout animals have indi-
cated duodenal TRPV6 to be a major mediator of 1,25-
(OH)2D3-mediated calcium absorption from intestine and
hypercalcemia [15]. Therefore, the weak agonist activity of
compoundAinhumanintestinalcellspredictedthatitmight
be less calcemic than 1,25-(OH)2D3 in vivo.I no r d e rt o
test this hypothesis, compound A was administered orally
to mice in a 6-day murine model of hypercalcemia. The
nonsecosteroidal VDRM was found to be at least 300 times
less potent than 1,25-(OH)2D3 in inducing hypercalcemia
by the oral route (Figure 7). The reduced calcemic liability
of compound A prompted us to test it in a murine EAE
model of MS. 1,25-(OH)2D3 and its secosteroidal analogs
havebeenshowntoameliorateEAE[6,27].Here,wedemon-
strate that treatment of MOG-immunized animals with the
nonsecosteroidal VDRM, compound A, delayed the onset of
EAE and resulted in a less severe course of disease during
the entire treatment period (Figure 8(a)). 1,25-(OH)2D3 on
the other hand showed eﬃcacy initially (till day 17 of the
treatment)and delayed theonset of the disease. Interestingly,
compound A did not raise the serum calcium levels above
the normal range whereas 1,25-(OH)2D3 treatment of MOG
immunized animals resulted in hypercalcemia (Figure 8(c)).Autoimmune Diseases 13
A plethora of epidemiological and pharmacological data
demonstrating the connection between vitamin D and MS,
coupledwithourobservationthatanonsecosteroidalVDRM
ameliorates EAE, strongly supports the use of noncalcemic
VDRMsasattractivecandidates forthe prevention and treat-
ment of MS. Since VDR ligands have diﬀerent mechanism
of action from currently approved MS treatment, they may
be more eﬃcacious and useful in a combination therapeutic
regimen.
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